Insulin-Like Growth Factor I
Research News and Information

Sunday, November 22, 2009

Acromegaly pathogenesis and treatment.

31 Oct 2009 Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly - a disorder of disproportionate skeletal, tissue, and organ growth. High GH and IGF1 levels lead to comorbidities ... Read more...

Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats.

30 Oct 2009 BACKGROUND: Chemoprevention utilizing dietary agents is an effective means to slow the development of prostate cancer. We evaluated the potential additive and synergistic effects of genistein and resveratrol for suppressing prostate cancer in the ... Read more...

Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.

30 Oct 2009 Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly-associated growth hormone secreting ... Read more...

Latest indexed articles for 'Insulin-Like Growth Factor I'

These are the very latest articles for this heading:

• Acromegaly pathogenesis and treatment. 31 Oct 2009
• Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. 30 Oct 2009
• Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. 30 Oct 2009
• The TC10-Exo70 complex is essential for membrane expansion and axonal specification in developing neurons. 19 Oct 2009
• Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. 11 Oct 2009
• Anabolic actions of IGF-I and TGF-beta1 on Interleukin-1beta-treated human articular chondrocytes: evaluation in two and three dimensional cultures. 29 Sep 2009
• High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. 29 Sep 2009
• Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons. 29 Sep 2009
• Histological and molecular analysis of the biceps tendon long head post-tenotomy. 29 Sep 2009
• Bronchial carcinoid secreting insulin-like growth factor-1 with acromegalic features. 29 Sep 2009
• IGF-1 released by corneal epithelial cells induces up-regulation of N-cadherin in corneal fibroblasts. 29 Sep 2009
• Partial primary deficiency of insulin-like growth factor (IGF)-I activity associated with IGF1 mutation demonstrates its critical role in growth and brain development. 20 Sep 2009
• Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. 14 Sep 2009
• Low-birth weight children develop lower sex hormone binding globulin and higher dehydroepiandrosterone sulfate levels and aggravate their visceral adiposity and hypoadiponectinemia between six and eight years of age. 6 Sep 2009
• Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes. 2 Sep 2009
• Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. 2 Sep 2009
• Role of IGF-I in skeletal muscle mass maintenance. 31 Aug 2009
• Setting the pace for retinal development: environmental enrichment acts through insulin-like growth factor 1 and brain-derived neurotrophic factor. 31 Aug 2009
• IGF-I maintains calpastatin expression and attenuates apoptosis in several models of photoreceptor cell death. 30 Aug 2009
• Mechanisms of growth impairment in pediatric Crohn's disease. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Insulin-Like Growth Factor I'

Definition: A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor.

Chemical name: Insulin-like growth factor I

Registry Number: 67763-96-6

Descriptor UI: D007334

Alternative terms: Insulin-Like Growth Factor I; Insulin-Like Somatomedin Peptide I; Insulin Like Somatomedin Peptide I; Somatomedin C; IGF-I-SmC; IGF-1; IGF-I; Insulin Like Growth Factor I;

Related Mesh Headings: Receptor, IGF Type 1;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.937.400; D12.776.124.862.400; D12.776.467.937.400; D23.529.937.400;

History Note: 91(86); was see under SOMATOMEDINS 1986-90